Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers

被引：87

作者：

Tabernero, Josep ^{[1
,2
]}

Vyas, Malvika ^{[3
]}

Giuliani, Rosa ^{[4
]}

Arnold, Dirk ^{[5
]}

Cardoso, Fatima ^{[6
]}

Casali, Paolo G. ^{[7
]}

Cervantes, Andres ^{[8
]}

Eggermont, Alexander M. M. ^{[9
]}

Eniu, Alexandru ^{[10
]}

Jassem, Jacek ^{[11
]}

Pentheroudakis, George ^{[12
]}

Peters, Solange ^{[13
]}

Rauh, Stefan ^{[14
]}

Zielinski, Christoph C. ^{[15
]}

Stahel, Rolf A. ^{[16
]}

Voest, Emile ^{[17
]}

Douillard, Jean-Yves ^{[3
]}

McGregor, Keith ^{[3
]}

Ciardiello, Fortunato ^{[18
]}

机构：

[1] Univ Autonoma Barcelona, Vall dHebron Univ Hosp, Barcelona, Spain

[2] Univ Autonoma Barcelona, VHIO, Barcelona, Spain

[3] European Soc Med Oncol, Lugano, Switzerland

[4] San Camillo Forlanini Hosp, Med Oncol, Rome, Italy

[5] CUF Hosp, Canc Ctr, Lisbon, Portugal

[6] Champalimaud Clin Ctr, Breast Unit, Lisbon, Portugal

[7] Fondaz IRCCS Natl Canc Inst, Milan, Italy

[8] Clin Hosp, Hematol Med Oncol Dept, Valencia, Spain

[9] Gustave Roussy Canc Campus Grand Paris, Villejuif, France

[10] Canc Inst Ion Chiricuta, Dept Breast Tumors, Cluj Napoca, Romania

[11] Med Univ Gdansk, Dept Oncol & Radiotherapy, Gdansk, Poland

[12] Univ Ioannina, Ioannina, Greece

[13] Univ Vaudois, Ctr Hospitalier, Oncol Dept, Lausanne, Switzerland

[14] Hosp Ctr Emile Mayrisch, Dept Hemato Oncol, Esch Sur Alzette, Luxembourg

[15] Med Univ Vienna, Dept Med 1, Clin Div Oncol, Vienna, Austria

[16] Netherlands Canc Inst, Amsterdam, Netherlands

[17] Univ Hosp Zurich, Zurich, Switzerland

[18] Univ Naples 2, Naples, Italy

来源：

ESMO OPEN | 2016年 / 1卷 / 06期

关键词：

Biobetters; Biosimilars; Cancer Treatment; Generics; Health Financial Burden; Non-comparable Biosimilars;

D O I：

10.1136/esmoopen-2016-000142

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

physicians, patients and healthcare systems. If suitably developed clinically, manufactured to the correct standards and used appropriately, they can positively impact on the financial sustainability of healthcare systems. A critical consideration regarding the introduction of biosimilars into the clinic centres on the required information concerning all the respective procedures. This position paper aims to describe the issues revolving around biosimilars that are relevant to the field of oncology, especially the prescribers. More specifically, we discuss aspects related to definition, forms of biosimilars, labelling, extrapolation, interchangeability, switching, automatic substitution, clinical standards on safety and efficacy, responsibilities among prescribers and pharmacists, potential impact on financial burden in healthcare and the current scenario and future prospects of biosimilars in Europe and the rest of the world.

引用

页数：5

共 50 条

[1] Reply to 'Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers'
Bakalos, Georgios
Schreitmueller, Thomas
ESMO OPEN, 2017, 2 (04)
[2] Knowledge and use of biosimilars in oncology: a survey by the European Society for Medical Oncology
Giuliani, Rosa
Tabernero, Josep
Cardoso, Fatima
McGregor, Keith Hanson
Vyas, Malvika
de Vries, Elisabeth G. E.
ESMO OPEN, 2019, 4 (02)
[3] The off-label use of drugs in oncology: a position paper by the European Society for Medical Oncology (ESMO)
Casali, P. G.
ANNALS OF ONCOLOGY, 2007, 18 (12) : 1923 - 1925
[4] European Society for Medical Oncology (ESMO) position paper on supportive and palliative care
Jordan, K.
Aapro, M.
Kaasa, S.
Ripamonti, C. I.
Scotte, F.
Strasser, F.
Young, A.
Bruera, E.
Herrstedt, J.
Keefe, D.
Laird, B.
Walsh, D.
Douillard, J. Y.
Cervantes, A.
ANNALS OF ONCOLOGY, 2018, 29 (01) : 36 - 43
[5] Adolescents and young adults (AYA) with cancer: a position paper from the AYA Working Group of the European Society for Medical Oncology (ESMO) and the European Society for Paediatric Oncology (SIOPE)
Ferrari, A.
Stark, D.
Peccatori, F. A.
Fern, L.
Laurence, V
Gaspar, N.
Bozovic-Spasojevic, I
Smith, O.
De Munter, J.
Derwich, K.
Hjorth, L.
van der Graaf, W. T. A.
Soanes, L.
Jezdic, S.
Blondeel, A.
Bielack, S.
Douillard, J-Y
Mountzios, G.
Saloustros, E.
ESMO OPEN, 2021, 6 (02)
[6] SOCIETY FOR PEDIATRIC ONCOLOGY AND HEMATOLOGY - A POSITION PAPER
WINKLER, K
KLINISCHE PADIATRIE, 1995, 207 (04): : 133 - 135
[7] European Society for Medical Oncology 2020
Rupert Bartsch
memo - Magazine of European Medical Oncology, 2021, 14 : 130 - 131
[8] European Society for Medical Oncology 2020
Bartsch, Rupert
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2021, 14 (02) : 130 - 131
[9] European Society of Medical Oncology (ESMO)
Kibble, A.
DRUGS OF THE FUTURE, 2020, 45 (11) : 849 - 859
[10] American Society of Clinical Oncology Statement: Biosimilars in Oncology
Lyman, Gary H.
Balaban, Edward
Diaz, Michael
Ferris, Andrea
Tsao, Anne
Voest, Emile
Zon, Robin
Francisco, Michael
Green, Sybil
Sherwood, Shimere
Harvey, R. Donald
Schilsky, Richard L.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (12) : 1260 - +

← 1 2 3 4 5 →